Free Shipping in the U.S. for orders over $1000.  Shop Now>>

KRT13 Antibodies

Cytokeratin 13 (CK13) is a protein encoded by the KRT13 gene on chromosome 17q21.2 in humans. It typically comprises 458 amino acids with a molecular weight of around 50 kDa. Post-translational modifications of CK13 include phosphorylation, glycosylation, and the formation of disulfide bonds, which contribute to its structural stability and functional diversity. CK13 is primarily an intracellular protein, forming intermediate filaments that provide structural support and integrity to epithelial cells. Moreover, this protein plays a role in cytoskeletal organization and epithelial differentiation, contributing to tissue resilience and protection against mechanical stress and pathogens.

CK13 is predominantly expressed in stratified squamous epithelia, with high levels observed in tissues such as the oral mucosa, esophagus, and cervix. Various factors, including developmental cues, hormonal signals, and tissue-specific transcription factors, regulate its expression. Dysregulation of CK13 expression has been associated with several oral mucosal disorders, including oral lichen planus and oral leukoplakia. Additionally, aberrant CK13 expression patterns have been observed in certain cancers, such as head and neck squamous cell carcinoma, where CK13 expression may serve as a diagnostic marker and provide insights into tumor differentiation and prognosis.

NeoBiotechnologies offers a variety of antibodies against CK13 that have been validated for flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting. Additionally, we hold exclusive rights to CK13 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/?s=KRT13].

Synonyms

Keratin, type I cytoskeletal 13, Cytokeratin-13, Keratin-13, CK13; Cytokeratin-13; Keratin Type I Cytoskeletal 13; Keratin-13; KRT13; Type I Cytoskeletal 13; WSN2

Research Areas

Developmental Biology

Showing all 4 results

KRT13

Showing all 4 results

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK